|
Enhanced Discounts (Merck/Sanofi/Pfizer)
Updated pricing sheets were sent out to CPP Buying Group members last week based on your level of participation with each of our vendor partners. If you missed them, please contact the CPP office at cpp@nationwidechildrens.org.
These updates reflect discount enhancements across all portfolios, including discounts linked to pediatric RSV immunization purchase options (Sanofi’s Beyfortus and Merck’s Enflonsia).
CPP members will see cost savings with either RSV immunization option, along with additional vaccine product discounts. The level of savings will vary based on your purchasing decisions and product mix.
The new pricing goes into effect July 1, 2026 (Merck and Pfizer) and September 1, 2026 (Sanofi). Please review your options and determine the product(s) that will work best for your group clinically, operationally and financially.
Contact CPP if you have questions about your updated pricing or if you need us to put together a customized cost analysis. If you’re considering changes to your vaccine portfolio, the CPP team is happy to review your current purchasing strategy and help identify the most cost-effective solution for your practice. We want to make this process easier for you.
As a reminder, when considering immunization options, CPP recommends evaluating the clinical and operational aspects of available products. For clinical guidance, please contact your Sanofi or Merck representative. If you do not have a representative, Contact CPP and we can help connect you with the experts at Sanofi and Merck.
| 
